In April 2018 CARB-X awarded Specific Diagnostics up to $3.4 million and then in July 2019 extended that support to $5.1 million to support the development of Specific's Reveal AST/ID system. CARB-X is investing $455 million over five years into the research and development of new antibiotics, rapid diagnostics and other life-saving products to tackle the global threat of drug-resistant bacteria. Kevin Outterson, Executive Director of CARB-X said, "Specific Diagnostics' project is an example of cutting edge technology that could potentially speed up and change the way life-threatening infections are diagnosed and treated. The world urgently needs new diagnostics, antibiotics, vaccines and other products to protect us from current and emerging drug-resistant bacteria”.
Honored by NIH
Specific has been awarded more than $20 million dollars in grants in support of the development of innovative diagnostic systems to combat blood-based infections and enable other transformative paradigms across the largest concerns in global healthcare.
Making a global impact with FIND
We have partnered with FIND, the world-leading non-profit dedicated to accelerating the development, evaluation and use of high-quality, affordable diagnostic tests for poverty-related diseases. In collaboration, we will enable solutions for diagnosis of bloodstream infections around the globe.